Daniel Mccoy Email & Phone Number

Lake Forest, IL, US

• Preclinical lead overseeing gene therapy programs in the metabolic and neurological disease spaces.
• Work closely with program SMEs, internal CMC, Regulatory, Clinical, and C-suite leadership to ensure safe and timely advancement of preclinical assets to IND.
• Responsible for the design and execution of in vivo proof of concept and pivotal IND-enablingpharmacology/biodistribution/safety studies for AAV-based gene therapy products

Lake Forest, IL, US

Lake Forest, IL, US

Palo Alto, California, US

Palo Alto, California, US

• Preclinical program scientific lead tasked with supporting the development of gene therapy products from vector design through IND-enabling in vivo studies
• AAV vector design/optimization, small scale viral production/process development, preclinical assay development, in vivo POC/ROA/DRF/Tox study design and biodistribution support
• Primary point of contact responsible for early stage program vector design and optimization

Durham, North Carolina, US

• Lead the Platform Development team (3 direct report career scientists)
• Responsible for the design and evolution of synthetic AAV capsids for various gene therapyindications (CNS, Liver, Eye – related)
• Responsible for the development of novel molecular and cell-based assays and SOPs to meetcorporate goals and milestones
• One of the first two lab-based hires of the company, in charge of setting up lab R&D operations
• Part of the management team and intimately involved in the hiring and growth of the company (from 2 – over 25 full time employees)

Durham, North Carolina, US

Brentford, Middlesex, GB

• Developing resident immune cell polarization assays in human ex vivo skin to model inflammatory skin disease states and support the development of relevant therapeutics
• Developed a lipid gene based endpoint assay to evaluate candidate molecules targeting lipogenesis-related pathways
• Contribute to both biomarker strategy, and transcriptomic disease signature study design/execution/characterization interfacing with external vendors and the GSK Computational Biology group
• Contributed to the target engagement data package for the candidate selection (CS) milestone for a GSK asset
• Designed proposals, wrote protocols, and managed external CRO contracts and academic collaborations

Durham, North Carolina, US

• Developed complex plate-based primary neuronal co-culture assays and assay endpoints for neurodegenerative disease research. In these cultures, primary cortical and striatal neurons are cultured together on a bed of.
• Screened novel therapeutics for toxicity and target engagement for pathways relevant to Huntington’s Disease

Los Angeles, CA, US

• “The expected and unexpected roles of TRPM8: Cold Pain and Metabolism”Project: 1) TRPM8 pore dilation can deliver therapeutics to cold-pain sensing neurons2) Enhanced insulin clearance in mice lacking functional TRPM8.
• Utilized extensive molecular cloning, live cell imaging, and mouse in vivo techniques toindependently develop 6 unique transgenic mouse models for studying the roles of TransientReceptor Potential (TRP) ion channels in.
• Characterized a channel pore dilation model in vitro demonstrating that cationic therapeutics canbe delivered to cold-pain sensory neurons in a highly specific manner. Results particularly noveland impactful as it was.
• Discovered and published a novel insulin clearance phenotype for the thermosensory channelTRPM8 with therapeutic implications in regards to the treatment of diabetes and other metabolic disorders

Paris, France, FR

• Worked in the Bio-therapeutics department supporting the development of ACAM529, a preclinical vaccine against HSV-2 (genital herpes)
• Supported both formulation and process development studies carrying out viral plaque assays and data quantification
• Developed a chemiluminescent Southern blot protocol for identifying modified viral HSV-2 DNA in complementing cell lines
• Carried out optimization studies for in house viral plaque assay SOP and presented findings to the ACAM529 team

New York, New York, US

• Worked in the Biomarker Discovery department handling clinical samples in efforts to identify candidates for various inflammatory diseases (psoriasis, asthma etc.)
• Performed ELISA analysis to support studies on inflammatory cytokine candidates and processed clinical samples for gene chip analysis (RNA extraction, quantification and stability studies using a Bioanalyzer)

Cambridge, MA, US

• Worked as a summer intern in the Discovery Neurobiology department (2004+2005)
• Cloned and expressed a neuroinflammatory receptor candidate in various soluble truncated forms
• Worked with mammalian cell lines and the drosophila S3 cell line for expression of truncationvariants. Expression was analyzed by Western blot

Phd, Molecular Biology

Bs, Biology